CJC-1295 and ipamorelin have generally demonstrated a low rate of serious adverse events in the small, short-term clinical trials conducted thus far. However, neither compound has been studied long enough or widely enough in humans to speak definitively about their overall safety. Several commonly discussed side effects – such as skin flushing or water retention – are also not well-documented in the controlled studies reviewed for this article. This guide separates what has actually been reported in clinical studies from what remains anecdotal or theoretical—which is critically important when assessing claims about the safety of unapproved compounds.
The side effects of CJC-1295 may include: * Injection site reactions (redness, pain, itching) * Headache * Dizziness * Nausea * Flushing * Fatigue * Increased appetite * Water retention * Joint pain There is limited research on the long-term effects of CJC-1295, so other potential side effects may exist. It is important to discuss any concerns or potential side effects with a healthcare professional before using CJC-1295.
The most direct clinical safety data for CJC-1295 comes from the initial human study, which included two randomised, double-blind, placebo-controlled trials in healthy adults. This study specifically noted that there were no serious adverse reactions, with researchers considering doses of 30 or 60 micrograms per kilogram of body weight to be safe and relatively well tolerated [1]. However, it is worth noting that the statement „no serious adverse reactions” is quite general, and the originally published study does not provide a detailed, itemised breakdown of every minor side effect experienced by participants - which limits how precisely this article can describe the full picture of symptoms.
A broader review from 2026, analysing performance-enhancing peptides targeting the growth hormone–IGF-1 axis, covering CJC-1295 in both DAC and non-DAC forms alongside ipamorelin, described a wider range of adverse events reported in this class of compounds in both clinical and self-administered contexts. These included endocrine and metabolic disturbances, such as elevated prolactin and cortisol, appetite changes, and dysglycaemia (abnormal regulation of blood sugar levels), as well as fluid retention, musculoskeletal symptoms like muscle or joint pain, and injection site reactions [2].
It is important to note that this review broadly encompassed the entire category of growth hormone secretagogues and GHRH analogues, drawing on both peer-reviewed pharmacokinetic evidence and patterns observed in real-world self-administration, rather than reporting a controlled number of side effects specific solely to CJC-1295. These findings should therefore be understood as representative of the entire class of compounds, rather than a confirmed, enumerated side-effect profile of CJC-1295.
CJC-1295 and ipamorelin cause skin flushing due to their effects on blood vessels. Both are growth hormone secretagogues, meaning they stimulate the pituitary gland to release more growth hormone. Growth hormone has various effects on the body, including vasodilation, which is the widening of blood vessels. This vasodilation leads to increased blood flow to the skin, which can manifest as redness or flushing. Additionally, some studies suggest that CJC-1295, in particular, may have a direct effect on histamine release, which can also contribute to vasodilation and flushing.
Skin flushing, water retention, and numbness or tingling are frequently mentioned in informal user reports or anecdotes. However, controlled clinical trials reviewed for this article do not specifically document flushing as a measured or reported adverse effect of CJC-1295 or ipamorelin, and thus a confirmed physiological explanation for flushing cannot be provided based on this evidence base. Water retention can be stated as having been described as one of the untoward effects associated with growth hormone axis-modulating peptides more broadly, including CJC-1295 and ipamorelin, in the review above. This is generally consistent with well-established general endocrinology, where growth hormone and IGF-1 are known to affect the body's fluid balance [2]. However, this article cannot state with certainty that flushing specifically has a confirmed mechanism related to CJC-1295 or ipamorelin, as this particular symptom was not identified as a documented finding in the reviewed peer-reviewed sources.
Injection site reactions – such as redness, irritation, or discomfort at the injection site – are listed in the same broader safety review of peptides as a recognised adverse effect within this class of compounds. This is a likely and commonplace occurrence with essentially any subcutaneously administered peptide, though again, this reflects a general finding across the drug category, rather than a controlled measurement specific to CJC-1295 [2]. Given these gaps, any detailed claims about exactly why or how often redness, numbness, or tingling occurs with CJC-1295 or ipamorelin should be treated as anecdotal rather than clinically established.
Are CJC-1295 and ipamorelin safe?
Neither CJC-1295 nor ipamorelin can be accurately described as „safe” or „unsafe” in an absolute sense. The honest answer is that the short-term data from small, controlled study populations appear reassuring, whilst the long-term safety profile under general, unsupervised use remains genuinely unknown. For ipamorelin, one of the most informative sets of safety data comes from a randomised, placebo-controlled phase 2 clinical trial in patients undergoing bowel resection. Ipamorelin was administered as an intravenous infusion twice daily for up to seven days under close medical supervision. In this trial, the overall incidence of any treatment-related adverse event was 87.5% in the ipamorelin group, compared with 94.8% in the placebo group – meaning that adverse events were no more frequent with ipamorelin than with placebo in this specific surgical population [3].
This is a significant data point, but it comes from a hospitalised, closely monitored surgical population receiving a specific low IV dose for a specific medical purpose. It doesn't necessarily reflect what would happen with self-administered subcutaneous injections for weeks or months in a healthy, non-hospitalised individual seeking muscle growth or anti-aging effects.
For CJC-1295, the safety data are similarly reassuring, yet equally limited in scope, relying on short trial periods of 28–49 days in healthy volunteers under clinical supervision [1]. Many recent scientific reviews covering this entire category of growth hormone axis peptides have clearly highlighted this gap, stating that rigorous human safety data remain sparse for many of these unapproved compounds, and that there is a real potential for harm when they are used outside monitored clinical settings – particularly given the inconsistent product quality in the unregulated peptide supply chain [4], [5]. In short, the available short-term evidence has not shown alarming safety signals. However, „not shown to be dangerous in a small, short study” is a very different statement from „proven safe for long-term use”, and the current evidence does not support the latter claim.
Allergic reaction to CJC-1295 and ipamorelin
No published clinical trials reviewed for this article have specifically documented allergic or hypersensitivity reactions to CJC-1295 or ipamorelin. This means that it remains an area without direct evidence, rather than one that can confidently be described as low or high risk. As a general rule in peptide pharmacology, any injected peptide – including growth hormone secretagogues such as these – carries the theoretical possibility of eliciting an immune or allergic response in an individual, as peptides can in principle be recognised by the immune system as foreign material. However, this is a general pharmacological consideration, not a documented finding specific to CJC-1295 or ipamorelin.
As dedicated data regarding hypersensitivity or contraindications for these specific compounds has not been identified in the reviewed peer-reviewed literature, this article cannot list specific allergy symptoms, risk factors, or contraindications with certainty. Doing so would carry the risk of presenting fabricated or unsupported information as fact.
What the evidence shows, and what remains unknown
| Question about security | What does the evidence show | Level of evidence |
|---|---|---|
| Serious adverse events (CJC-1295, short-term) | No [1] adverse events were reported in the main human study at doses of 30–60 mcg/kg. | Clinical on humans (small study, short duration) |
| Overall incidence of adverse events (ipamorelin, surgical patients) | 87.51 TP30T (ipamorelin) vs 94.81 TP30T (placebo); no increase compared with placebo [3] | Clinical trial on humans (specific surgical population) |
| Fluid retention, musculoskeletal symptoms, injection site reactions | Described as the effects of the entire class of growth hormone axis peptides in recent reviews [2] | An overview of the broader peptide category, not isolated CJC-1295/ipamorelin data |
| Redness of the skin | Undocumented in the reviewed controlled studies | Anecdotal/unverified |
| Numbness or tingling | Undocumented in the reviewed controlled studies | Anecdotal/unverified |
| Allergic reactions/hypersensitivity | No dedicated data identified | Theoretical, based on general peptide pharmacology |
| Long-term safety (months to years) | Not investigated in any identified study | Unknown/No data |
Limitations of current evidence
The safety profile for CJC-1295 and ipamorelin is built almost entirely on short-term studies – weeks, not months or years – conducted on small, highly selected, and closely monitored populations: healthy volunteers for CJC-1295 and hospitalised surgical patients for the most detailed adverse event data on ipamorelin.
Neither of these scenarios reflects how these compounds are typically used outside of clinical trials, and many recent reviews explicitly acknowledge that long-term human safety data simply does not yet exist for this class of peptides [4], [5]. Commonly cited side effects, such as skin redness, water retention, and numbness at the injection site, frequently appear in informal or commercial discussions of these compounds.
Disclaimer
This content is for educational purposes only and does not constitute medical advice, diagnosis, or therapeutic recommendation. CJC-1295 and ipamorelin are research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used individually or in combination. The safety information presented here reflects findings from short-term clinical studies in small, closely monitored populations and does not constitute confirmed long-term safety data.
References
[1] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[2] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, Article 1822475. https://doi.org/10.3389/fendo.2026.1822475
Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014-2030-8
[4] Mendias, C. L., & Awan, T. M. (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. Advance online publication. https://doi.org/10.1007/s40279-026-02437-0
[5] Coutinho, L. F. D., De Oliveira Neves, L. F., & Camilo, R. P. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: A critical review. Journal of Sports Medicine and Physical Fitness, 66(7), 880–885. https://doi.org/10.23736/S0022-4707.26.17773-1